Oncotarget

Meta-Analysis:

Association between depression and brain tumor: a systematic review and meta-analysis

Jing Huang, Chao Zeng, Juxiong Xiao, Danwei Zhao, Hui Tang, Haishan Wu and Jindong Chen _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:94932-94943. https://doi.org/10.18632/oncotarget.19843

Metrics: PDF 1101 views  |   HTML 1657 views  |   ?  


Abstract

Jing Huang1,2, Chao Zeng3, Juxiong Xiao4, Danwei Zhao5, Hui Tang1,2, Haishan Wu1,2 and Jindong Chen1,2

1Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

2Mental Health Institute of The Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (Xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan, China

3Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, Changsha, Hunan, China

4Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China

5Xiangya Medical School, Central South University, Changsha, Hunan, China

Correspondence to:

Jindong Chen, email: 1048534957@qq.com

Keywords: brain tumor, depression, depressive disorder, depressive symptoms, meta-analysis

Received: March 02, 2017    Accepted: June 04, 2017    Published: August 03, 2017

ABSTRACT

Background: Patients with brain tumor are in risk of depression or depressive symptoms, but the estimated prevalence varies between studies. The aim of this study is to get a proper summarized estimate of depression prevalence in brain tumor patients.

Methods: Literature search on Pubmed, PsycINFO, and Cochrane library from January 1981 through October 2016. The prevalence of depression or depressive symptoms in brain tumor patients was estimated by screening scales and analyzed using stratified meta-analysis and subgroup analysis. The prevalence of depression level or symptoms during the follow-up periods was detected by secondary analysis.

Results: Among the 37 studies included in this meta-analysis, 25 used a cross-sectional design and 12 used longitudinal study. The pooled prevalence was 21.7% (971/4518 individuals, 95 % confidence interval (CI) 18.2%–25.2%) for overall sample. Lower prevalence was detected in studies with sample size ≥100 than <100, lower grade tumor than high grade tumor, studies using clinician-rated depression scales than self-rated or non-depression-specific ones, and in patients from UK, Germany and Italy than USA. After analyzing 6 longitudinal studies, prevalence of depression remained no change in the follow-up periods. No significant differences were observed between study designs and tumor types.

Conclusions: The estimated prevalence of depression or depressive symptoms among brain tumor patients was 21.7%, affected by depression assessment type, sample size, tumor grade and country. Diagnosis and treatment of co-morbid depression in brain tumor patients need to be addressed in future studies for better life quality and oncology management.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19843